Bruker has entered into a definitive agreement to buy preclinical in-vivo imaging products and its related assets from Carestream Health's molecular imaging business.
Under the agreement, Carestream will retain the remaining assets of its molecular imaging business including its life science X-ray film product lines and its Gel Logic and Image Station in-vitro imaging equipment product portfolio.
The terms of Bruker’s deal with Carestream have not been disclosed.
Bruker BioSpin president Werner Maas said the company believes that Carestream’s optical molecular imaging product line will complement its other preclinical solutions, presently consisting of magnetic resonance imaging, magnetic particle imaging and X-ray micro computed tomography.
"We also welcome the talented Carestream in-vivo employees to Bruker, and look forward to their contributions," Maas added.